ANALYTICAL SERVICES CENTER FOR MEDICATIONS DEVELOPMENT PROGRAM. SEPTEMBER 25, 2019 - SEPTEMBER 24, 2020. N01DA-19-8938. TASK ORDER 1 - 75N95019F00088.

该合同的目的是提供生物分析化学资源，以支持NIDA的药物开发计划。有待开发的新药物包括新的分子实体以及重新定位用于治疗sud的上市药物。药物开发是一个漫长而复杂的过程。NIDA通过拨款和合同支持药物开发工作的各个方面，包括合成、药剂学、生物分析化学、药理学、毒理学/毒代动力学、药代动力学(PK)/代谢和潜在药物的临床评估。该合同将作为一个集中的生物分析设施，以支持临床前PK/毒代动力学研究、临床药理学/PK研究和临床试验，以评估研究药物的有效性和安全性。

The purpose of this contract is to provide bioanalytical chemistry resources to support NIDA's medications development program. New medications to be developed include new molecular entities as well as marketed drugs repositioned for the treatment of SUDs. Medication development is a long and complex process. NIDA supports every aspect of the medications development efforts including syntheses, pharmaceutics, bioanalytical chemistry, pharmacology, toxicology/toxicokinetics, pharmacokinetics (PK)/metabolism and clinical evaluations of potential medications through grants and contracts. This contract will serve as a centralized bioanalytical facility to support the preclinical PK/toxicokinetic studies, clinical pharmacology/PK studies and clinical trials for assessing the efficacy and safety of the study medications.